WO2008021432A3 - Compositions and methods for treatment of conditions affecting the nervous system - Google Patents

Compositions and methods for treatment of conditions affecting the nervous system Download PDF

Info

Publication number
WO2008021432A3
WO2008021432A3 PCT/US2007/018138 US2007018138W WO2008021432A3 WO 2008021432 A3 WO2008021432 A3 WO 2008021432A3 US 2007018138 W US2007018138 W US 2007018138W WO 2008021432 A3 WO2008021432 A3 WO 2008021432A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
treatment
nervous system
methods
conditions affecting
Prior art date
Application number
PCT/US2007/018138
Other languages
French (fr)
Other versions
WO2008021432A2 (en
Inventor
Andrew Robert Marks
Original Assignee
Univ Columbia
Andrew Robert Marks
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/506,285 external-priority patent/US7879840B2/en
Priority claimed from PCT/US2006/032405 external-priority patent/WO2007024717A2/en
Application filed by Univ Columbia, Andrew Robert Marks filed Critical Univ Columbia
Publication of WO2008021432A2 publication Critical patent/WO2008021432A2/en
Publication of WO2008021432A3 publication Critical patent/WO2008021432A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides methods and compositions for the treatment and prevention of diseases, disorders, and conditions affecting the nervous system, such as neuropathies, seizures, and disorders affecting the cognitive functioning. The present invention also provides methods and compositions for improving cognitive function in the absence or presence of a specific cognitive disease, disorder or condition.
PCT/US2007/018138 2006-08-17 2007-08-15 Compositions and methods for treatment of conditions affecting the nervous system WO2008021432A2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US11/506,285 US7879840B2 (en) 2005-08-25 2006-08-17 Agents for preventing and treating disorders involving modulation of the RyR receptors
USPCT/US2006/32405 2006-08-17
PCT/US2006/032405 WO2007024717A2 (en) 2005-08-25 2006-08-17 Agents for preventing and treating disorders involving modulation of the ryr receptors
US11/506,285 2006-08-17
US90420607P 2007-03-01 2007-03-01
US60/904,206 2007-03-01
US80947007A 2007-06-01 2007-06-01
US11/809,470 2007-06-01

Publications (2)

Publication Number Publication Date
WO2008021432A2 WO2008021432A2 (en) 2008-02-21
WO2008021432A3 true WO2008021432A3 (en) 2008-11-06

Family

ID=39082729

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/018138 WO2008021432A2 (en) 2006-08-17 2007-08-15 Compositions and methods for treatment of conditions affecting the nervous system

Country Status (1)

Country Link
WO (1) WO2008021432A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
EP2708535A1 (en) 2012-05-11 2014-03-19 Les Laboratoires Servier Agents for treating disorders involving modulation of ryanodine receptors
WO2022150603A1 (en) 2021-01-08 2022-07-14 Armgo Pharma, Inc. Crystalline forms of a ryanodine receptor modulator and uses thereof
US11717526B2 (en) 2021-05-20 2023-08-08 Armgo Pharma, Inc. Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998005657A1 (en) * 1996-08-02 1998-02-12 Knoll Aktiengesellschaft 2,3-dihydro-1,4-benzothiazepines, their preparation and their use as intermediates

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998005657A1 (en) * 1996-08-02 1998-02-12 Knoll Aktiengesellschaft 2,3-dihydro-1,4-benzothiazepines, their preparation and their use as intermediates

Also Published As

Publication number Publication date
WO2008021432A2 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
WO2008067121A3 (en) Methods of treating cognitive impairment and dementia
WO2007109120A3 (en) Imidazolothiazole compounds for the treatment of disease
WO2008021210A3 (en) Methods and compositions for the treatment of neurodegenerative disorders
WO2007009120A3 (en) Heterotetracyclic compounds as tpo mimetics
WO2007038610A3 (en) Use of natural products for treatment of neurological disorders
WO2008153705A3 (en) Methods of treating, diagnosing and detecting fgf21-associated disorders
WO2007111994A3 (en) Compounds and methods for treatment of disorders associated with er stress
WO2008011476A3 (en) Compositions and methods for modulating sirtuin activity
WO2006083533A3 (en) Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
MX2009006536A (en) Organic compounds and their uses.
WO2008076754A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009009491A (en) Compounds and compositions as modulators of gpr119 activity.
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
WO2007022269A3 (en) Compounds and compositions as tpo mimetics
WO2007024971A3 (en) Hedgehog pathway antagonists to treat disease
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2006034491A3 (en) Phenyl-substituted quinoline and quinazoline compounds for the treatment of diabetes
WO2008073463A3 (en) Methods and compositions for treating and monitoring treatment of il-13-associated disorders
WO2007051785A3 (en) Use of sdf-1 for the treatment and/or prevention of neurological diseases
WO2009009417A3 (en) Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion
WO2009116037A3 (en) NOVEL siRNA COMPOUNDS FOR INHIBITING RTP801
WO2007112121A3 (en) Tetracycline compounds and methods of treatment
WO2007101063A3 (en) Treatment of development-related disorders
WO2005112923A3 (en) 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07811360

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07811360

Country of ref document: EP

Kind code of ref document: A2